Access

Letter


Nature Medicine 13, 492 - 497 (2007)
Published online: 1 April 2007 | doi:10.1038/nm1561

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

Katarzyna Maresz1,11, Gareth Pryce2,10,11, Eugene D Ponomarev1, Giovanni Marsicano3, J Ludovic Croxford2,4, Leah P Shriver1,5, Catherine Ledent6, Xiaodong Cheng1, Erica J Carrier7, Monica K Mann1,5, Gavin Giovannoni2,10, Roger G Pertwee8, Takashi Yamamura4, Nancy E Buckley9, Cecilia J Hillard7, Beat Lutz3, David Baker2,10,11 & Bonnie N Dittel1,5,11


The cannabinoid system is immunomodulatory and has been targeted as a treatment for the central nervous system (CNS) autoimmune disease multiple sclerosis. Using an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we investigated the role of the CB1 and CB2 cannabinoid receptors in regulating CNS autoimmunity. We found that CB1 receptor expression by neurons, but not T cells, was required for cannabinoid-mediated EAE suppression. In contrast, CB2 receptor expression by encephalitogenic T cells was critical for controlling inflammation associated with EAE. CB2-deficient T cells in the CNS during EAE exhibited reduced levels of apoptosis, a higher rate of proliferation and increased production of inflammatory cytokines, resulting in severe clinical disease. Together, our results demonstrate that the cannabinoid system within the CNS plays a critical role in regulating autoimmune inflammation, with the CNS directly suppressing T-cell effector function via the CB2 receptor.


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Viral damage and the breakdown of self-tolerance

Nature Medicine News and Views (01 Oct 1997)

Multiple sclerosis: trapped in deadly glue

Nature Medicine News and Views (01 Mar 2005)